February 27, 2013
Biotech firm Endo Health Solutions (NASDAQ: ENDP ) announced in a press release recently that it has named former Valeant Pharmaceuticals (NYSE: VRX ) President Rajiv De Silva as the company's new CEO, replacing retiring CEO David Holveck.
De Silva has served with Valeant since 2009, also acting as the company's chief operating officer of its specialty pharmaceuticals branch. He expressed his excitement in the statement, pledging to commit to top-line growth, improve cost management, and create shareholder value.
Endo Chairman of the Board Roger H. Kimmel expressed his own thoughts in the statement, saying, "[De Silva's] track record in generating growth and profitability, managing complex integrations, and delivering for shareholders will serve us well."